Phosphatidylserine Health Claims in Europe: A Pre-Launch Review

European supplement brands should review phosphatidylserine health claims as a finished-product and commercial-communication decision, not as a phrase supplied with the raw material. A study, technical presentation, ingredient brochure, or competitor label may inform research, but none of those items automatically authorises wording on a label, product page, advertisement, retailer listing, or social post.

The practical buyer question is therefore not simply, “What are the benefits of phosphatidylserine?” It is, “Which exact statements can this exact formula use in the intended European markets, under which conditions, and with which internal approval?” That question needs regulatory, formulation, quality, procurement, and marketing input before packaging is printed or digital campaigns go live.

This guide explains a controlled review process for phosphatidylserine, soy phosphatidylserine, and sunflower phosphatidylserine projects. It is operational guidance, not legal advice.

The Short Answer for European Supplement Brands

Do not use a cognitive, memory, stress, mental-performance, or other health-related statement for a phosphatidylserine supplement in Europe merely because the formula contains PS or because supporting research exists. First identify whether the wording is a nutrition claim, a specific health claim, a general non-specific health reference, or a prohibited disease-related statement. Then check the current EU Register, the underlying legal act, every condition of use, the finished formula and daily portion, the surrounding presentation, and any national requirements in the countries where the product will be sold.

The European Commission defines a health claim as a statement about a relationship between a food and health. Regulation (EC) No 1924/2006 applies to claims made in commercial communications, including labelling, presentation, and advertising. Its Article 10 framework generally prohibits health claims unless they comply with the Regulation, are authorised, and appear in the relevant lists.

For phosphatidylserine specifically, a 2010 EFSA opinion evaluated submitted Article 13(1) claimed effects concerning memory and cognitive functioning, mental health or cognitive function, and stress reduction or enhanced memory. EFSA concluded that the constituent was not sufficiently characterised in relation to the claimed effects and that a cause-and-effect relationship could not be established from the submitted material. That is a critical evidence checkpoint. It is not permission to restate those proposed effects, and it should not be simplified into a claim of efficacy or into a blanket legal conclusion detached from the current Register.

Why Ingredient Approval and Claim Approval Are Different

A permitted ingredient route does not create a permitted benefit statement

Ingredient status answers whether and under what conditions a particular ingredient may be placed on the market or used in specified foods. Claim status answers whether a particular nutrition or health message may be used and under which conditions. These reviews interact, but one cannot substitute for the other.

A brand may complete a phosphatidylserine novel-food review for Europe and still need a separate claim decision. It may also confirm the correct ingredient designation and allergen presentation through a soya phosphatidylserine labelling review without resolving the front-of-pack benefit language.

The approval file should separately confirm the ingredient and source route, finished-product compliance, each voluntary claim and its conditions, and whether the overall presentation remains accurate and non-misleading. Closing only the ingredient question is not a launch approval.

The review extends beyond the physical label

Regulation (EC) No 1924/2006 covers commercial communications, while Regulation (EU) No 1169/2011 applies accuracy and non-misleading principles to food information and extends key rules to advertising and presentation. A carefully reviewed carton can therefore be undermined by an uncontrolled product-detail page, paid advertisement, marketplace bullet, influencer brief, email campaign, trade-show panel, or distributor catalogue.

For online sales, food information also needs to satisfy distance-selling rules. Use one master copy deck for every channel, owned by the responsible European food business operator or importer. The ingredient supplier can support the raw-material file but cannot approve the buyer's finished formula, consumer wording, national notification, or campaign context.

Four EU Claim Rules That Shape the Decision

Start with the exact claim, food, and conditions of use

The EU Register is a reference point for authorised and non-authorised health claims, their conditions, restrictions, and related legal acts. Search results should be treated as the beginning of a controlled review. Record the exact substance, authorised wording, permissible flexibility in wording, target population, required quantity, consumption pattern, warnings, restrictions, and the date on which the record was checked.

Do not stop at a keyword resemblance. A claim authorised for another nutrient in a multi-ingredient formula is not a phosphatidylserine claim. The formula must satisfy that claim's conditions, and the presentation must identify the relevant component. Nutrition claims have their own permitted list and conditions; even a factual declaration can shift toward a health message through context.

Read the PS-specific EFSA opinion as an evidence checkpoint

The 2010 EFSA opinion is useful because it shows why identity and evidence scope matter. The submitted material involved uncertainty about the phosphatidylserine source and the generalisation of evidence across different source materials and combinations. EFSA's conclusion addressed the constituent and claimed effects considered in that opinion.

For buyers, three practical lessons follow:

• Never merge evidence for different PS sources, compositions, carriers, or combinations without a justified bridge.
• Do not convert an observed endpoint in a study into broader consumer wording.
• Do not present an EFSA scientific opinion, a research paper, or a supplier summary as if it were an authorisation in the EU Register.

Scientific substantiation and legal authorisation are connected but not interchangeable. Marketing should not extract a phrase from research while regulatory checks only the ingredient name.

General wellness language still needs a compliant foundation

Broad phrases about overall good health or health-related well-being may sound softer than a specific health claim, but Article 10(3) does not make them a free category. Commission Implementing Decision 2013/63/EU explains that a general, non-specific health reference must be accompanied by a relevant specific health claim from the permitted lists. The specific claim should be next to or follow the general reference, and the operator must be able to demonstrate the link.

This affects front-of-pack phrases, icons, product names, benefit categories, and marketplace bullets. Broad “mind,” “focus,” “brain,” “calm,” or “wellness” concepts can still imply a health relationship in context. Review the complete consumer impression.

Disease prevention, treatment, and cure language is outside the food route

Directive 2002/46/EC states that the labelling, presentation, and advertising of food supplements must not attribute to them the property of preventing, treating, or curing a human disease or refer to such properties. Regulation (EU) No 1169/2011 applies the same core boundary to food information, advertising, and presentation.

A disclaimer cannot rescue disease wording that should not be used for a food supplement. Testimonials, targeting, graphics, hashtags, and linked landing pages also belong in the review.

A Seven-Step Phosphatidylserine Claims Review Workflow

Lock the exact product and market route

Start with the sellable product, not a generic “PS formula.” Record the PS source, commercial grade, other ingredients, dosage form, recommended daily portion, target population, food category, brand owner, responsible EU operator or importer, sales countries, languages, and intended channels.

State whether the formula uses soy PS, sunflower PS, or another route, because evidence, ingredient designation, allergen review, novel-food assessment, and claim presentation must refer to the same material.

Build one inventory of every consumer-facing statement

Collect the exact words, visuals, and placements from the packaging front, back, side panels, website, marketplace listing, advertisements, search snippets, distributor copy, social content, sales sheets, and campaign briefs. Include product names, category labels, icons, imagery, hashtags, testimonials, and implied comparisons.

Assign an owner and version to every item. Save screenshots where imagery or placement changes the consumer impression.

Classify each statement before debating the wording

Place every item into a working category:

• mandatory or factual product information;
• a nutrition claim;
• a specific health claim;
• a general, non-specific health reference;
• a disease-risk-reduction or children's-development claim requiring its own authorised route;
• disease prevention, treatment, or cure wording that is not suitable for a food supplement;
• non-health lifestyle or sensory language that still needs a misleading-information check.

When the category is unclear, hold the copy for regulatory escalation. Rewording without classification creates inconsistent channel decisions.

Search the current EU Register and legal act

For each proposed nutrition or health claim, search the current EU Register and open the related legal act. Record the review date, exact substance, status, authorised wording, conditions, restrictions, required statements, and the internal conclusion.

For PS-related wording, include the 2010 EFSA opinion in the evidence file. Do not rely on an old screenshot, search summary, competitor page, or claim list copied from another market.

Match the formula, daily portion, and presentation to the conditions

An authorised claim is usable only when its conditions are met. Verify the amount delivered by the recommended daily portion, the relevant measurement basis, target population, consumption pattern, warnings, and any other restrictions. Make sure the formulation master, specification, finished-product testing plan, label quantity, and marketing statement describe the same product.

Article 10 also requires claim context, including a varied and balanced diet and healthy lifestyle statement, the quantity and consumption pattern needed for the effect, and applicable warnings. Directive 2002/46/EC separately requires the recommended daily portion, a warning not to exceed it, a varied-diet statement, and storage out of reach of young children.

Separate supplier evidence from finished-product responsibility

Ask the PS supplier for current, source-specific evidence needed to identify and control the material: specification, representative or current batch COA as appropriate, composition and source information, manufacturing context, packaging information, storage guidance, and document revision status. Use manufacturing evidence, Qualidade e P&D, and the PS ingredient document checklist to organise the supplier file.

Do not ask the supplier to guarantee a finished-product claim that depends on the complete formula, daily portion, target consumer, artwork, website, and country of sale. The buyer's responsible operator and qualified advisers must approve that finished presentation.

Complete Member State, language, and approval checks

EU rules provide a common framework, but Member States may require notification of a food supplement for monitoring, and national provisions, competent-authority practice, and language requirements still matter. Build a market matrix showing the responsible entity, notification path, label language, national reviewer, launch date, and any country-specific open item.

Close with a signed go, hold, or remove decision for each statement. Archive approved artwork and digital copy together; later formula, serving, source, audience, or campaign changes should trigger re-review.

A Practical Claims Review Matrix

Need Source-Specific PS Documents for the Review?

If your regulatory file still describes only “phosphatidylserine” without a stable source, grade, composition, and daily-use context, pause the claim review. Send Nutranexa the source path, target product format, destination countries, forecast quantity, and current document list through the contact page. Nutranexa can support the ingredient-identification and supplier-document portion of the file; the finished-product operator retains responsibility for formulation, claims, artwork, notification, and market approval.

Common Pre-Launch Mistakes to Prevent

1. Treating a scientific paper or supplier presentation as an authorised claim.
2. Assuming an ingredient's permitted market route also permits a benefit statement.
3. Copying cognitive or stress wording from a US product, competitor label, or retailer page into EU artwork.
4. Using a broad wellness phrase without checking whether it is a general non-specific health reference that needs an accompanying permitted claim.
5. Relying on an authorised claim for another formula component while visually attributing the benefit to PS.
6. Reviewing the carton but not the product page, advertisements, marketplace copy, testimonials, and distributor catalogue.
7. Checking wording without checking the formula, recommended daily portion, target population, and conditions of use.
8. Allowing source, serving, artwork, or campaign changes after approval without reopening the decision.

A short claims register is more reliable than scattered approval emails.

How Verified Nutranexa Facts Support Claim-Safe Sourcing

Nutranexa presents separate general, soy, and sunflower phosphatidylserine paths. The company states that it was founded in 2013, operates a 110,000+ m2 campus, focuses exports primarily on Europe and North America, and supports R&D cooperation. Public manufacturing, packaging, dispatch, specification, and COA context can support preliminary supplier qualification.

For phosphatidylserine, Nutranexa publishes a 25 kg MOQ and 25 kg net-per-drum baseline. These facts help procurement frame a commercial inquiry, but they do not decide a finished-product claim. Buyers should request current evidence for the exact PS item and keep it aligned with their formula master, artwork, claim register, and market matrix.

Nutranexa supports source-specific ingredient and supply information; the responsible European operators and advisers decide the finished product's use, claims, notification, and advertising.

Fontes

• European Commission: Nutrition and Health Claims
• European Commission: EU Register of Health Claims
• EUR-Lex: Regulation (EC) No 1924/2006 on nutrition and health claims made on foods
• EUR-Lex: Commission Regulation (EU) No 432/2012 establishing the list of permitted Article 13 health claims
• EUR-Lex: Commission Implementing Decision 2013/63/EU on Article 10 guidance
• EFSA Journal: Scientific Opinion on health claims related to phosphatidyl serine
• EUR-Lex: Directive 2002/46/EC on food supplements
• EUR-Lex: Regulation (EU) No 1169/2011 on food information to consumers
• European Commission: Food Supplements and Member State Monitoring

Perguntas frequentes

Can a phosphatidylserine supplement make a memory or cognitive claim in the EU?

Do not assume it can. Check the exact proposed wording in the current EU Register and related legal act. The 2010 EFSA opinion on submitted phosphatidylserine effects concerning memory, cognitive function, mental health, and stress concluded that the constituent was not sufficiently characterised for those effects and that a cause-and-effect relationship could not be established from the submitted material.

Does published research make a phosphatidylserine health claim legal in Europe?

No. Research may be relevant to scientific assessment, but a commercial health claim must also follow Regulation (EC) No 1924/2006, be authorised where required, appear in the applicable permitted list, and meet its conditions of use. A study title, supplier summary, or competitor citation is not an EU claim authorisation.

Can a brand use a general phrase such as brain wellness or mental well-being?

It requires careful review. If consumers are likely to understand the phrase as a general, non-specific health benefit, Article 10(3) requires it to be accompanied by a relevant specific health claim from the permitted lists. Product names, icons, imagery, placement, and surrounding copy affect the overall interpretation.

Can an authorised claim for another nutrient be used on a formula that also contains PS?

Potentially, if the finished formula meets every condition for that authorised claim and the presentation accurately identifies the component to which the claim relates. The artwork should not imply that the authorised benefit belongs to phosphatidylserine when the legal basis is another nutrient.

Who approves the final phosphatidylserine claim for European sales?

The food business operator responsible for the finished product, or the importer where applicable, should control the final food information and obtain qualified regulatory or legal review. The PS supplier can support source identity, specification, COA, manufacturing, packaging, storage, and related ingredient documents, but it cannot approve the buyer's complete formula, artwork, digital campaign, national notification, or market-specific claim.

Conclusion

A defensible European phosphatidylserine claim review starts with the exact finished product and exact consumer message. Classify every statement, search the current EU Register and legal act, understand the PS-specific EFSA evidence checkpoint, verify formula and daily-portion conditions, review all physical and digital channels, and close Member State and language requirements before launch.

If the statement category, legal basis, conditions, and full consumer impression are not recorded, hold the wording before print or publication.

Próximas etapas recomendadas

• Revise o Phosphatidylserine página do produto.
• Comparar Soy PS e Sunflower PS.
• Verifique prova de fabricação e Qualidade e P&D.